9 research outputs found
Human Umbilical Cord Therapy Improves Long-Term Behavioral Outcomes Following Neonatal Hypoxic Ischemic Brain Injury
Background: Hypoxic ischemic (HI) insult in term babies at labor or birth can cause long-term neurodevelopmental disorders, including cerebral palsy (CP). The current standard treatment for term infants with hypoxic ischemic encephalopathy (HIE) is hypothermia. Because hypothermia is only partially effective, novel therapies are required to improve outcomes further. Human umbilical cord blood cells (UCB) are a rich source of stem and progenitor cells making them a potential treatment for neonatal HI brain injury. Recent clinical trials have shown that UCB therapy is a safe and efficacious treatment for confirmed cerebral palsy. In this study, we assessed whether early administration of UCB to the neonate could improve long-term behavioral outcomes and promote brain repair following neonatal HI brain injury.Methods: HI brain injury was induced in postnatal day (PND) 7 rat pups via permanent ligation of the left carotid artery, followed by a 90 min hypoxic challenge. UCB was administered intraperitoneally on PND 8. Behavioral tests, including negative geotaxis, forelimb preference and open field test, were performed on PND 14, 30, and 50, following brains were collected for assessment of neuropathology.Results: Neonatal HI resulted in decreased brain weight, cerebral tissue loss and apoptosis in the somatosensory cortex, as well as compromised behavioral outcomes. UCB administration following HI improved short and long-term behavioral outcomes but did not reduce long-term histological evidence of brain injury compared to HI alone. In addition, UCB following HI increased microglia activation in the somatosensory cortex compared to HI alone.Conclusion: Administration of a single dose of UCB cells 24 h after HI injury improves behavior, however, a single dose of cells does not modulate pathological evidence of long-term brain injury
Supervision of thrombolysis of acute myocardial infarction using telemedicine
The treatment of acute myocardial infarction (MI) constitutes a
significant problem in remote geographical areas of Greece. Furthermore,
thrombolysis, the treatment of choice in the early phase of acute MI,
requires the supervision of an expert. We have used thrombolytic
treatment, using telemedicine, in remote medical centres. The Onassis
Cardiac Surgery Centre was linked to six remote Aegean islands via
telemedicine systems which permitted the transmission of 12-lead
electrocardiograms (ECGs). The thrombolytic agent anistreplase was
administered to patients with acute MI. Supervision, including
consultation for treatment of complications, was achieved using the
telemedicine system. One hundred and fifty-two ECGs were transmitted
during 24 months, of which 108 (71%) indicated specific treatment of a
cardiac condition. Ten cases were diagnosed as having acute MI and eight
of these were treated with anistreplase. All patients survived acute MI
and complications were treated locally. The application of thrombolytic
treatment in acute MI is feasible in remote areas, with the use of a
telemedicine system
Effects of Maternal Sildenafil Treatment on Vascular Function in Growth-Restricted Fetal Sheep
Human umbilical cord therapy improves long-term behavioral outcomes following neonatal hypoxic ischemic brain injury
Background: Hypoxic ischemic (HI) insult in term babies at labor or birth can cause long-term neurodevelopmental disorders, including cerebral palsy (CP). The current standard treatment for term infants with hypoxic ischemic encephalopathy (HIE) is hypothermia. Because hypothermia is only partially effective, novel therapies are required to improve outcomes further. Human umbilical cord blood cells (UCB) are a rich source of stem and progenitor cells making them a potential treatment for neonatal HI brain injury. Recent clinical trials have shown that UCB therapy is a safe and efficacious treatment for confirmed cerebral palsy. In this study, we assessed whether early administration of UCB to the neonate could improve long-term behavioral outcomes and promote brain repair following neonatal HI brain injury.Methods: HI brain injury was induced in postnatal day (PND) 7 rat pups via permanent ligation of the left carotid artery, followed by a 90 min hypoxic challenge. UCB was administered intraperitoneally on PND 8. Behavioral tests, including negative geotaxis, forelimb preference and open field test, were performed on PND 14, 30, and 50, following brains were collected for assessment of neuropathology.Results: Neonatal HI resulted in decreased brain weight, cerebral tissue loss and apoptosis in the somatosensory cortex, as well as compromised behavioral outcomes. UCB administration following HI improved short and long-term behavioral outcomes but did not reduce long-term histological evidence of brain injury compared to HI alone. In addition, UCB following HI increased microglia activation in the somatosensory cortex compared to HI alone.Conclusion: Administration of a single dose of UCB cells 24 h after HI injury improves behavior, however, a single dose of cells does not modulate pathological evidence of long-term brain injury.</p
Multiple doses of umbilical cord blood cells improve long-term brain injury in the neonatal rat
Dictionnaire des intellectuel.les au Québec
Qui connaît vraiment les intellectuel.les hors du cercle restreint des historiens et des littéraires ? Quelle mémoire avons-nous de celles et ceux qui, au Québec, eurent recours à la parole comme « mode d'action » ? Qui, comme Hubert Aquin, entreprirent et entreprennent encore de « comprendre dangereusement » la culture et la société de leur époque, remuant idées et images, bousculant pouvoirs et doxa ? Ce dictionnaire est conçu pour combler les lacunes d'une mémoire collective quelque peu défaillante, mais aussi pour donner envie de lire ou de relire les textes de ces femmes et hommes passionnés par les idées, qui ont contribué - et qui contribuent toujours - à bâtir la société québécoise. On y trouvera les noms de celles et ceux qui, depuis trois siècles, interviennent sur la place publique et soulèvent des questions d'intérêt civique et politique à propos d'enjeux collectifs importants ; de celles et ceux qui promeuvent ou incarnent la liberté de parole et la défendent contre différents pouvoirs et structures organisationnelles
Dictionnaire
ACTION FRANÇAISE (1917-1928) / ACTION NATIONALE (1933- ) Lancée une dizaine d’années après l’affaire Dreyfus, L’Action française (AF) de Montréal existe toujours sous le titre L’Action nationale (AN). C’est dire la place de la revue pour l’histoire des intellectuels, d’autant plus qu’au-delà de La Revue canadienne (1864-1922) et des journaux nationalistes du début du siècle – Le Nationaliste (1903) d’Olivar Asselin*, L’Action (1911-1916) de Jules Fournier*, Le Devoir (1910) d’Henri Bourassa* ..
Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: The ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology
Aims: The aim of this study was to determine the contemporary use of reperfusion therapy in the European Society of Cardiology (ESC) member and affiliated countries and adherence to ESC clinical practice guidelines in patients with ST-elevation myocardial infarction (STEMI). Methods and results: Prospective cohort (EURObservational Research Programme STEMI Registry) of hospitalized STEMI patients with symptom onset <24 h in 196 centres across 29 countries. A total of 11 462 patients were enrolled, for whom primary percutaneous coronary intervention (PCI) (total cohort frequency: 72.2%, country frequency range 0-100%), fibrinolysis (18.8%; 0-100%), and no reperfusion therapy (9.0%; 0-75%) were performed. Corresponding in-hospital mortality rates from any cause were 3.1%, 4.4%, and 14.1% and overall mortality was 4.4% (country range 2.5-5.9%). Achievement of quality indicators for reperfusion was reported for 92.7% (region range 84.8-97.5%) for the performance of reperfusion therapy of all patients with STEMI <12 h and 54.4% (region range 37.1-70.1%) for timely reperfusion. Conclusions: The use of reperfusion therapy for STEMI in the ESC member and affiliated countries was high. Primary PCI was the most frequently used treatment and associated total in-hospital mortality was below 5%. However, there was geographic variation in the use of primary PCI, which was associated with differences in in-hospital mortality
The ESC ACCA EAPCI EORP acute coronary syndrome ST-elevation myocardial infarction registry
Aims: The Acute Cardiac Care Association (ACCA)-European Association of Percutaneous Coronary Intervention (EAPCI) Registry on ST-elevation myocardial infarction (STEMI) of the EurObservational programme (EORP) of the European Society of Cardiology (ESC) registry aimed to determine the current state of the use of reperfusion therapy in ESC member and ESC affiliated countries and the adherence to ESC STEMI guidelines in patients with STEMI. Methods and results: Between 1 January 2015 and 31 March 2018, a total of 11 462 patients admitted with an initial diagnosis of STEMI according to the 2012 ESC STEMI guidelines were enrolled. Individual patient data were collected across 196 centres and 29 countries. Among the centres, there were 136 percutaneous coronary intervention centres and 91 with cardiac surgery on-site. The majority of centres (129/196) were part of a STEMI network. The main objective of this study was to describe the demographic, clinical, and angiographic characteristics of patients with STEMI. Other objectives include to assess management patterns and in particular the current use of reperfusion therapies and to evaluate how recommendations of most recent STEMI European guidelines regarding reperfusion therapies and adjunctive pharmacological and non-pharmacological treatments are adopted in clinical practice and how their application can impact on patients' outcomes. Patients will be followed for 1 year after admission. Conclusion: The ESC ACCA-EAPCI EORP ACS STEMI registry is an international registry of care and outcomes of patients hospitalized with STEMI. It will provide insights into the contemporary patient profile, management patterns, and 1-year outcome of patients with STEMI